Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sky Century InvestmentSKYI -25.37% Debt-to-EBITDA is 4.59 as of May. 2026. The stock has 5 warning signs investors should review. Among 677 Drug Manufacturers companies, Sky Century Investment ranks worse than 147710.34% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Sky Century Investment's Debt-to-EBITDA or its related term are showing as below:
SKYI'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -49 Med: -2.3 Max: -1.86
Current: -49
During the past 6 years, the highest Debt-to-EBITDA Ratio of Sky Century Investment was -1.86. The lowest was -49.00. And the median was -2.30.
SKYI's Debt-to-EBITDA is ranked worse than 100% of 677
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs SKYI: -49.00
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Sky Century Investment Debt-to-EBITDA Related Terms
Sky Century Investment Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Sky Century Investment's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SKYI vs CBDY, NPHC, CBIH: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sky Century Investment's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sky Century Investment Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sky Century Investment's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sky Century Investment's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (May. 2026) EBITDA data.
Sky Century Investment (SKYI) has a Debt-to-EBITDA of 4.59 as of May. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sky Century Investment. According to the industry distribution chart, Sky Century Investment ranks #999999 out of 677 companies in the Drug Manufacturers industry.
Is Sky Century Investment's Debt-to-EBITDA too high?
Sky Century Investment's current Debt-to-EBITDA is 4.59. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. Sky Century Investment's value of 4.59 is 179.9% above this industry median. Based on the distribution chart, Sky Century Investment ranks #999999 out of 677 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Sky Century Investment's Debt-to-EBITDA compare to CBDY and NPHC?
According to the Drug Manufacturers industry distribution chart, Sky Century Investment ranks #999999 out of 677 companies for Debt-to-EBITDA. This places Sky Century Investment in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. Sky Century Investment's value of 4.59 is 179.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 677 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sky Century Investment's current Debt-to-EBITDA of 4.59 is 179.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sky Century Investment. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sky Century Investment's current Debt-to-EBITDA is 4.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sky Century Investment stock overvalued right now?
Sky Century Investment (SKYI) has a current Debt-to-EBITDA of 4.59. The current Debt-to-EBITDA is 4.59 and 179.9% above the Drug Manufacturers industry median of 1.64. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Sky Century Investment (SKYI), the current Debt-to-EBITDA is 4.59 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sky Century Investment Inc operates four primary business lines, with profits generated from IT Services, including Technical Support and Server Leasing, and from the sale of RSS feeds and Podcasts. The IT Services segment provides ongoing technical support, maintenance, system upgrades, and high-performance server leasing, supporting growing demand for cloud solutions, data management, and network infrastructure. The Company also owns the Cannabis News application, a mobile platform that aggregates cannabis-related news from diverse sources and delivers real-time updates, though it is not commercially viable and has not generated revenue to date. The Company operates in competitive markets across IT services, marketing services, RSS feed services, and the cannabis industry.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SKYI has been successfully added to your 
